Cardiorenal syndrome: Still not a defined entity

Clinical and Experimental Nephrology

Volumn 14, Issue 1, 2010, Pages 12-21

  Longhini, Carlo ^a   Molino, Christian ^a   Fabbian, Fabio ^a  

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Anemia; Chronic kidney disease; Diuretic therapy; Heart failure

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CONIVAPTAN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIXIVAPTAN; MOZAVAPTAN; NITRIC OXIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; REACTIVE OXYGEN METABOLITE; RECOMBINANT ERYTHROPOIETIN; SATAVAPTAN; SPIRONOLACTONE; TOLVAPTAN; VASOPRESSIN ANTAGONIST;

ADRENERGIC SYSTEM; AGING; ANEMIA; BLOOD TRANSFUSION; BLOOD VOLUME; CARDIORENAL SYNDROME; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIURETIC THERAPY; HEART FAILURE; HEART OUTPUT; HUMAN; INCIDENCE; INFLAMMATION; KIDNEY BLOOD FLOW; MORTALITY; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

AGED; ANEMIA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PRESSURE; CARDIAC OUTPUT; DIURETICS; HEART FAILURE; HEMODYNAMICS; HUMANS; KIDNEY FAILURE, CHRONIC; PROGNOSIS; RENAL CIRCULATION;

EID: 77649182782     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-009-0257-4     Document Type: Review

References (100)

1. C Ronco M Haapio AA House N Anavekar R Bellomo 2008 Cardiorenal syndrome J Am Coll Cardiol 52 1527 1539 10.1016/j.jacc.2008.07.051 19007588
2. P Gil S Justo MA Castilla C Criado C Caramelo 2005 Cardio-renal insufficiency: the search for management strategies Curr Opin Nephrol Hypertens 14 442 447 10.1097/01.mnh.0000170753.41279.70 16046902
3. G Boerrigter JC Burnett Jr 2004 Cardiorenal syndrome in decompensated heart failure: prognostic and therapeutic implications Curr Heart Fail Rep 1 113 120 10.1007/s11897-004-0020-9 16036034
4. HL Hillege AR Girbes PJ de Kam F Boomsma D de Zeeuw A Charlesworth JR Hampton DJ van Veldhuisen 2000 Renal function, neurohormonal activation, and survival in patients with chronic heart failure Circulation 102 203 210 1:STN:280:DC%2BD3czkvFeqtQ%3D%3D 10889132
5. MT Kearney KA Fox AJ Lee RJ Prescott AM Shah PD Batin W Baig S Lindsay TS Callahan WE Shell DL Eckberg AG Zaman S Williams JM Neilson J Nolan 2002 Predicting death due to progressive heart failure in patients with mild to-moderate chronic heart failure J Am Coll Cardiol 40 1801 1808 10.1016/S0735-1097(02)02490-7 12446064 (Pubitemid 35341959)
6. R Dumaine JP Collet ML Tanguy N Mansencal JL Dubois-Randé P Henry PG Steg PL Michel P Allouch A Cohen P Colin E Durand G Montalescot SYCOMORE Investigators 2004 Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study) Am J Cardiol 94 1543 1547 10.1016/j.amjcard.2004.08.035 15589013 (Pubitemid 40268459)
7. SG Coca HM Krumholz AX Garg CR Parikh 2006 Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease JAMA 296 1377 1384 10.1001/jama.296.11.1377 1:CAS:528:DC%2BD28XpvF2lsbw%3D 16985230 (Pubitemid 44427424)
8. HM Krumholz YT Chen V Vaccarino Y Wang MJ Radford WD Bradford RI Horwitz 2000 Correlates and impact on outcomes of worsening renal function in patients >65 years of age with heart failure Am J Cardiol 85 1110 1113 10.1016/S0002-9149(00)00705-0 1:STN:280:DC%2BD3c3ksFSksg%3D%3D 10781761 (Pubitemid 30214258)
9. JG Cleland K Swedberg F Follath M Komajda A Cohen-Solal JC Aguilar R Dietz A Gavazzi R Hobbs J Korewicki HC Madeira VS Moiseyev I Preda WH van Gilst J Widimsky N Freemantle J Eastaugh J Mason Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology 2003 The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis Eur Heart J 24 442 463 10.1016/S0195-668X(02)00823-0 1:STN:280:DC%2BD3s7itVWjug%3D%3D 12633546 (Pubitemid 36286187)
10. KF Adams Jr GC Fonarow CL Emerman TH LeJemtel MR Costanzo WT Abraham RL Berkowitz M Galvao DP Horton ADHERE Scientific Advisory Committee and Investigators 2005 Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Failure National Registry (ADHERE) Am Heart J 149 209 216 10.1016/j.ahj.2004.08.005 15846257 (Pubitemid 40348525)
11. DE Forman J Butler Y Wang WT Abraham CM O'Connor SS Gottlieb E Loh BM Massie MW Rich LW Stevenson JB Young HM Krumholz 2004 Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure J Am Coll Cardiol 43 61 67 10.1016/j.jacc.2003.07.031 14715185 (Pubitemid 38045917)
12. GC Fonarow KF Adams Jr WT Abraham CW Yancy WJ Boscardin For the ADHERE Scientific Advisory Committee, Study Group, and Investigators 2005 Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis JAMA 293 572 580 10.1001/jama.293.5.572 1:CAS:528:DC%2BD2MXhtVWqsLg%3D 15687312 (Pubitemid 40171239)
13. J Ezekowitz FA McAlister KH Humphries CM Norris M Tonelli WA Ghali ML Knudtson APPROACH Investigators 2004 The association among renal insufficiency, pharmacotherapy and outcomes in 6,427 patients with heart failure and coronary artery disease J Am Coll Cardiol 44 1587 1591 10.1016/j.jacc.2004.06.072 15489090 (Pubitemid 39369790)
14. GL Smith JH Lichtman MB Bracken MG Shlipak CO Phillips P DiCapua HM Krumholz 2006 Renal impairment and outcomes in heart failure: systematic review and meta-analysis J Am Coll Cardiol 47 1987 1996 10.1016/j.jacc.2005.11.084 16697315
15. L Grigorian Shamagian A Varela Román M Pedreira Pérez I Gómez Otero A Virgós Lamela JR González-Juanatey 2006 Renal failure is an independent predictor of mortality in hospitalized heart failure patients and is associated with a worse cardiovascular risk profile Rev Esp Cardiol 59 99 108 10.1157/13084636 16540030
16. G Cotter Y Moshkovitz O Milovanov A Salah A Blatt R Krakover Z Vered E Kaluski 2002 Acute heart failure: a novel approach to its pathogenesis and treatment Eur J Heart Fail 4 227 234 10.1016/S1388-9842(02)00017-X 12034145 (Pubitemid 35190344)
17. UC Brewster JF Setaro MA Perazella 2003 The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states Am J Med Sci 326 15 24 10.1097/00000441-200307000-00003 12861121
18. BJ Epstein 2004 Elevations in serum creatinine concentration: concerning or reassuring? Pharmacotherapy 24 697 702 10.1592/phco.24.6.697.34731 1:CAS:528:DC%2BD2cXlvVeltL4%3D 15162910 (Pubitemid 38585970)
19. V Sanchez JF Delgado JM Morales R Tello MA Gómez P Escribano AG de la Cámara CS de la Calzada 2004 Chronic cyclosporine induced nephrotoxicity in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine Transplant Proc 36 2823 2825 10.1016/j.transproceed.2004.09.035 1:CAS:528:DC%2BD2cXhtFGhtb7N 15621159 (Pubitemid 40036847)
20. H Yoshida M Yashiro P Liang E Muso E Takeuchi T Shimada K Sekita T Ono K Kanatsu T Sugiyama C Kawai S Sasayama 1998 Mesangiolytic glomerulopathy in severe congestive heart failure Kidney Int 53 880 891 10.1111/j.1523-1755.1998. 00830.x 1:STN:280:DyaK1c3ht1Omug%3D%3D 9551394
21. D Silverberg D Wexler M Blum D Schwartz A Iaina 2004 The association between congestive heart failure and chronic renal disease Curr Opin Nephrol Hypertens 13 163 170 10.1097/00041552-200403000-00004 1:CAS:528: DC%2BD2cXjt1Gqu7Y%3D 15202610 (Pubitemid 38373138)
22. JA Joles HA Koomans 2004 Causes and consequences of increased sympathetic activity in renal disease Hypertension 43 699 706 10.1161/01.HYP.0000121881. 77212.b1 1:CAS:528:DC%2BD2cXit12msb0%3D 14981063 (Pubitemid 38405571)
23. JD Firth AE Raine JG Ledingham 1988 Raised venous pressure: a direct cause of renal sodium retention in oedema? Lancet 1 1033 1035 10.1016/S0140-6736(88)91851-X 1:STN:280:DyaL1c3hsFOhug%3D%3D 2896877
24. DL Dries DV Exner MJ Domanski B Greenberg LW Stevenson 2000 The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction J Am Coll Cardiol 35 681 689 10.1016/S0735-1097(99)00608-7 1:STN:280:DC%2BD3c7nvFaitw%3D%3D 10716471 (Pubitemid 30167025)
25. HM Krumholz Y-T Chen Y Wang V Vaccarino MJ Radford RI Horwitz 2000 Predictors of readmission among elderly survivors of admission with heart failure Am Heart J 139 72 77 10.1016/S0002-8703(00)90311-9 1:STN:280: DC%2BD3c%2Fos1Cquw%3D%3D 10618565
26. MW Akhter D Aronson F Bitar S Khan H Singh RP Singh AJ Burger U Elkayam 2004 Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure Am J Cardiol 94 957 960 10.1016/j.amjcard.2004.06.041 1:CAS:528:DC%2BD2cXotFCmsbs%3D 15464689 (Pubitemid 39349569)
27. LG Bongartz MJ Cramer B Braam 2004 The cardiorenal connection [letter] Hypertension 43 e14 10.1161/01.HYP.0000118521.06245.b8 1:CAS:528: DC%2BD2cXjtVeksrg%3D 14967846
28. IA Reid 1992 Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure Am J Physiol 262 E763 E778 1:CAS:528:DyaK38XltVCgt78%3D 1616014
29. KK Griendling CA Minieri JD Ollerenshaw RW Alexander 1994 Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells Circ Res 74 1141 1148 1:CAS:528:DyaK2cXksFSlu7s%3D 8187280
30. B Hornig U Landmesser C Kohler D Ahlersmann S Spiekermann A Christoph H Tatge H Drexler 2001 Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase Circulation 103 799 805 1:CAS:528:DC%2BD3MXhs1WhtLs%3D 11171786
31. K Leineweber I Heinroth-Hoffmann K Pönicke G Abraham B Osten OE Brodde 2002 Cardiac beta adrenoceptor desensitization due to increased beta-adrenoceptor kinase activity in chronic uremia J Am Soc Nephrol 13 117 124 1:CAS:528:DC%2BD38XltV2gsw%3D%3D 11752028
32. T Bleeke H Zhang N Madamanchi C Patterson JE Faber 2004 Catecholamine-induced vascular wall growth is dependent on generation of reactive oxygen species Circ Res 94 37 45 10.1161/01.RES.0000109412.80157.7D 1:CAS:528:DC%2BD2cXhtFSq 14656924 (Pubitemid 38064096)
33. DS Silverberg D Wexler M Blum Y Wollman D Schwartz D Sheps G Keren A Iaina 2004 The interaction between heart failure, renal failure and anemia-the cardio-renal anemia syndrome Blood Purif 22 277 284 10.1159/000078698 15166489 (Pubitemid 39177732)
34. DS Silverberg D Wexler M Blum G Keren D Sheps E Leibovitch D Brosh S Laniado D Schwartz T Yachnin I Shapira D Gavish R Baruch B Koifman C Kaplan S Steinbruch A Iaina 2000 The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations J Am Coll Cardiol 35 1737 1744 10.1016/S0735-1097(00)00613-6 1:CAS:528:DC%2BD3cXktlGlt7Y%3D 10841219 (Pubitemid 30342851)
35. A Levin CR Thompson J Ethier EJ Carlisle S Tobe D Mendelssohn E Burgess K Jindal B Barrett J Singer O Djurdjev 1999 Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin Am J Kidney Dis 34 125 134 10.1016/S0272-6386(99)70118-6 1:STN:280:DyaK1MzjtV2hsg%3D%3D 10401026
36. LM Ruilope A Salvetti K Jamerson L Hansson I Warnold H Wedel A Zanchetti 2001 Renal insufficiency and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study J Am Soc Nephrol 12 218 225 1:STN:280:DC%2BD3M7mt1CjsQ%3D%3D 11158211
37. H Ikram W Chan EA Espiner MG Nicholls 1980 Haemodynamic and hormone responses to acute and chronic furosemide therapy in congestive heart failure Clin Sci 59 443 449 1:CAS:528:DyaL3MXhtlamsrc%3D 7002435 (Pubitemid 11168352)
38. JT Heywood 2005 Combining nesiritide with high-dose diuretics may increase the risk of increased serum creatinine J Card Fail 11 Suppl S154
39. RL Mehta MT Pascual S Soroko GM Chertow For the PICARD Study Group 2002 Diuretics, mortality, and nonrecovery of renal function in acute renal failure JAMA 288 2547 2553 10.1001/jama.288.20.2547 1:CAS:528:DC%2BD38XptFOgsr4%3D 12444861 (Pubitemid 35386889)
40. SH Kubo M Clark JH Laragh JS Borer RJ Cody 1987 Identification of normal neurohormonal activity in mild congestive heart failure and stimulating effect of upright posture and diuretics Am J Cardiol 60 1322 1328 10.1016/0002-9149(87) 90615-1 1:STN:280:DyaL1c%2FnsVSjsQ%3D%3D 3318370 (Pubitemid 18150301)
41. GW Neuberg AB Miller CM O'Connor RN Belkin PE Carson AB Cropp DJ Frid RG Nye ML Pressler JH Wertheimer M Packer PRAISE Investigators 2002 Prospective Randomized Amlodipine Survival Evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure Am Heart J 144 31 38 10.1067/mhj.2002.123144 12094185 (Pubitemid 34734752)
42. DC Brater 1998 Diuretic therapy N Engl J Med 339 387 395 10.1056/NEJM199808063390607 1:CAS:528:DyaK1cXltl2msLo%3D 9691107 (Pubitemid 28363803)
43. M Domanski J Norman B Pitt M Haigney S Hanlon E Peyster 2003 Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD) J Am Coll Cardiol 42 705 708 10.1016/S0735-1097(03)00765-4 1:CAS:528:DC%2BD3sXnsFerurY%3D 12932605 (Pubitemid 37000189)
44. F Ali M Guglin P Vaitkevicius JK Ghali 2007 Therapeutic potential of vasopressin receptor antagonists Drugs 67 847 858 10.2165/00003495-200767060- 00002 1:CAS:528:DC%2BD2sXmt1emtrk%3D 17428103
45. JG Verbalis 2006 AVP receptor antagonists as aquaretics: review and assessment of clinical data Cleve Clin J Med 73 Suppl 3 S24 S33 10.3949/ccjm.73.Suppl-3.S24 16970150
46. M Gheorghiade WA Gattis CM O'Connor KF Adams Jr U Elkayam A Barbagelata JK Ghali RL Benza FA McGrew M Klapholz J Ouyang C Orlandi 2004 Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial JAMA 291 1963 1971 10.1001/jama.291.16.1963 1:CAS:528:DC%2BD2cXjs1ajsb8%3D 15113814 (Pubitemid 38544277)
47. M Gheorghiade MA Konstam JC Burnett Jr L Grinfeld AP Maggioni K Swedberg JE Udelson F Zannad T Cook J Ouyang C Zimmer C Orlandi Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators 2007 Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials JAMA 297 1332 1343 10.1001/jama.297.12.1332 1:CAS:528:DC%2BD2sXjs1ejt7k%3D 17384438 (Pubitemid 46513234)
48. AC Schoolwerth DA Sica BJ Ballermann CS Wilcox 2001 Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association Circulation 104 1985 1991 10.1161/hc4101.096153 1:CAS:528:DC%2BD3MXosFGntbw%3D 11602506
49. U Elkayam G Tasissa C Binanay, et al. 2004 Use and impact of inotropes and vasodilator therapy during heart failure hospitalization in the ESCAPE Trial Circulation 110 Suppl 3 III-515
50. RJ DiDomenico HY Park MR Southworth HM Eyrich RK Lewis JM Finley GT Schumock 2004 Guidelines for acute decompensated heart failure treatment Ann Pharmacother 38 649 660 10.1345/aph.1D481 14982975 (Pubitemid 38352231)
51. WT Abraham KF Adams GC Fonarow MR Costanzo RL Berkowitz TH LeJemtel ML Cheng J Wynne ADHERE Scientific Advisory Committee and Investigators; ADHERE Study Group 2005 In-hospital mortality in patients with acute decompensated heart failure treated with intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE) J Am Coll Cardiol 46 57 64 10.1016/j.jacc.2005.03.051 15992636 (Pubitemid 40905130)
52. MS Nieminen J Akkila G Hasenfuss FX Kleber LA Lehtonen V Mitrovic O Nyquist WJ Remme 2000 Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure J Am Coll Cardiol 36 1903 1912 10.1016/S0735-1097(00)00961-X 1:CAS:528:DC%2BD3MXhs1Cm 11092663 (Pubitemid 30844104)
53. A Mebazaa MS Nieminen M Packer A Cohen-Solal FX Kleber SJ Pocock R Thakkar RJ Padley P Põder M Kivikko SURVIVE Investigators 2007 Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial JAMA 297 1883 1891 10.1001/jama.297.17.1883 1:CAS:528:DC%2BD2sXkvFKrsLs%3D 17473298 (Pubitemid 46707842)
54. K Chatterjee WW Parmley JN Cohn TB Levine NA Awan DT Mason DP Faxon M Creager HP Gavras FM Fouad, et al. 1985 A cooperative multicenter study of captopril in congestive heart failure: hemodynamic effects and long-term response Am Heart J 110 439 447 10.1016/0002-8703(85)90167-X 1:STN:280:DyaL2M3nsF2mtg%3D%3D 3895877 (Pubitemid 16054692)
55. M Packer WH Lee PD Kessler SS Gottlieb N Medina M Yushak 1987 Prevention and reversal of nitrate tolerance in patients with congestive heart failure N Engl J Med 317 799 804 1:STN:280:DyaL2szhsFanug%3D%3D 3114637 (Pubitemid 17136471)
56. LS Marcus D Hart M Packer M Yushak N Medina RS Danziger DF Heitjan SD Katz 1996 Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: a double-blind, placebo-controlled, randomized crossover trial Circulation 94 3184 3189 1:CAS:528:DyaK2sXks12quw%3D%3D 8989127
57. KL Januzzi 2006 Natriurtic peptide testing: a window into the diagnosis and prognosis of heart failure Cleve Clin J Med 73 149 157 10.3949/ccjm.73.2.149 16478039
58. SS Gottlieb DC Brater I Thomas E Havranek R Bourge S Goldman F Dyer M Gomez D Bennett B Ticho E Beckman WT Abraham 2002 BG 9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy Circulation 105 1348 1353 10.1161/hc1102.105264 1:CAS:528:DC%2BD38XjtFalsL4%3D 11901047 (Pubitemid 34260427)
59. U Elkayam H Singh MW Akhter, et al. 2004 Effects of intravenous nesiritide on renal hemodynamics in patients with congestive heart failure J Card Fail 10 Suppl 4 S88 10.1016/j.cardfail.2004.06.255
60. WT Abraham 2005 Serum creatinine elevations in patients receiving nesiritide are related to starting dose J Card Fail 11 Suppl S156
61. U Elkayam 2005 Nesiritide may diminish the increased acute mortality risk associated with worsening renal function Circulation 112 Suppl II 676
62. PW Armstrong JL Rouleau 2008 A Canadian context for the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF) trial Can J Cardiol 24 Suppl B 30B 32B 1:CAS:528:DC%2BD1cXhtVWmt7zF 18629387
63. MM Dohadwala MM Givertz 2008 Role of adenosine antagonism in the cardiorenal syndrome Cardiovasc Ther 26 276 286 10.1111/j.1755-5922.2008.00059.x 1:CAS:528:DC%2BD1MXkt1ensA%3D%3D 19035879
64. RM Witteles D Kao D Christopherson K Matsuda RH Vagelos D Schreiber MB Fowler 2007 Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial J Am Coll Cardiol 50 1835 1840 10.1016/j.jacc.2007.03.071 1:CAS:528:DC%2BD2sXht1GlurzM 17980248 (Pubitemid 350007964)
65. S Ljungman JH Laragh RJ Cody 1990 Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function Drugs 39 Suppl 4 10 21 10.2165/00003495-199000394-00004 2354670
66. M Packer 1987 Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition Am J Cardiol 60 179 184 10.1016/0002-9149(87)91009-5 1:STN:280: DyaL2s3mslehug%3D%3D 3037878 (Pubitemid 17132122)
67. GL Bakris MR Weir V DeQuattro FG McMahon 1998 Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy Kidney Int 54 1283 1289 10.1046/j.1523-1755.1998.00083.x 1:CAS:528: DyaK1cXmslOju78%3D 9767545 (Pubitemid 28449916)
68. GL Bakris MR Weir 2000 Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 160 685 693 10.1001/archinte.160.5.685 1:CAS:528:DC%2BD3cXit1Smtr4%3D 10724055
69. G Singh G Triadafilopoulos 1999 Epidemiology of NSAID induced gastrointestinal complications J Rheumatol 26 Suppl 56 18 24
70. AG Johnson 1997 NSAIDs and increased blood pressure. What is the clinical significance? Drug Saf 17 277 289 10.2165/00002018-199717050-00001 1:CAS:528:DyaK2sXns1OhtbY%3D 9391772
71. GK Sandhu CA Heyneman 2004 Nephrotoxic potential of selective cyclooxygenase-2 inhibitors Ann Pharmacother 38 700 704 10.1345/aph.1D296 1:CAS:528:DC%2BD2cXjtFegsrw%3D 14982980 (Pubitemid 38352237)
72. Practice Guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 1996;84:732-47.
73. W Jelkmann 2004 Molecular biology of erythropoietin Intern Med 43 649 659 10.2169/internalmedicine.43.649 1:CAS:528:DC%2BD2cXhtVahsLbO 15468961 (Pubitemid 39264162)
74. DS Silverberg D Wexler D Sheps M Blum G Keren R Baruch D Schwartz T Yachnin S Steinbruch I Shapira S Laniado A Iaina 2001 The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study J Am Coll Cardiol 37 1775 1780 10.1016/S0735-1097(01)01248-7 1:CAS:528: DC%2BD3MXltVGhsL8%3D 11401110 (Pubitemid 32499958)
75. DM Mancini SD Katz CC Lang J LaManca A Hudaihed AS Androne 2003 Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure Circulation 107 294 299 10.1161/01.CIR.0000044914.42696.6A 1:CAS:528:DC%2BD3sXjt1Cgug%3D%3D 12538431 (Pubitemid 36135227)
76. JG Cleland JT Sullivan S Ball JD Horowitz B Agoram D Rosser W Yates L Tin P Fuentealba PB Burton 2005 Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation J Cardiovasc Pharmacol 46 155 161 10.1097/01.fjc.0000167013.77092.c4 1:CAS:528:DC%2BD2MXmsV2jtbk%3D 16044026 (Pubitemid 41060207)
77. DJ van Veldhuisen K Dickstein A Cohen-Solal DJ Lok SM Wasserman N Baker D Rosser JG Cleland P Ponikowski 2007 Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia Eur Heart J 28 2208 2216 10.1093/eurheartj/ehm328 17681958 (Pubitemid 47428946)
78. P Ponikowski SD Anker J Szachniewicz D Okonko M Ledwidge R Zymlinski E Ryan SM Wasserman N Baker D Rosser SD Rosen PA Poole-Wilson W Banasiak AJ Coats K McDonald 2007 Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure. A randomized, double-blind, placebo-controlled trial J Am Coll Cardiol 49 753 762 10.1016/j.jacc.2006.11.024 1:CAS:528:DC%2BD2sXhvVyhsbg%3D 17306703 (Pubitemid 46240705)
79. JT Parissis K Kourea F Panou D Farmakis I Paraskevaidis I Ikonomidis G Filippatos DT Kremastinos 2008 Effects of darbepoetin α on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy Am Heart J 155 751.e1 751.e7 10.1016/j.ahj.2008.01.016
80. JK Ghali IS Anand WT Abraham GC Fonarow B Greenberg H Krum BM Massie SM Wasserman ML Trotman Y Sun B Knusel P Armstrong Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group 2008 Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia Circulation 117 526 535 10.1161/CIRCULATIONAHA.107.698514 1:CAS:528:DC%2BD1cXotlCrtw%3D%3D 18195176
81. DS Silverberg D Wexler M Blum JZ Tchebiner D Sheps G Keren D Schwartz R Baruch T Yachnin M Shaked I Schwartz S Steinbruch 2003 Iaina A The effect of correction of anaemia in diabetics and nondiabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron Nephrol Dial Transplant 18 141 146 10.1093/ndt/18.1.141 1:CAS:528:DC%2BD38XpsFOntbk%3D 12480972 (Pubitemid 36104490)
82. E Fazlibegović M Hadziomerović S Corić E Babić F Fazlibegović 2006 Erythropoietin in cardiorenal anemia syndrome Bosn J Basic Med Sci 6 36 41 17177647
83. E Judith 2007 Mitchell. Emerging Role of Anemia in Heart Failure Am J Cardiol 99 suppl 15D 20D
84. J Valles MT Santos J Aznar M Martinez A Moscardo M Pinon MJ Broekman AJ Marcus 2002 Platelet-erythrocyte interactions enhance alpha(IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo Blood 99 3978 3984 10.1182/blood.V99.11.3978 1:CAS:528:DC%2BD38XktFyrs7s%3D 12010797 (Pubitemid 35332037)
85. B Fuste M Serradell G Escolar A Cases R Mazzara R Castillo A Ordinas M Diaz-Ricart 2002 Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro Thromb Haemost 88 678 685 12362243
86. ND Vaziri 1999 Mechanism of erythropoietin-induced hypertension Am J Kidney Dis 33 821 828 10.1016/S0272-6386(99)70413-0 1:CAS:528:DyaK1MXjtVWqsbk%3D 10213636
87. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis. 2001;37:S182-S238.
88. JL Sullivan 1999 Iron therapy and cardiovascular disease Kidney Int Suppl 69 S135 S137 10.1046/j.1523-1755.1999.055Suppl.69135.x 1:CAS:528: DyaK1MXhvVSnu7c%3D 10084298
89. H Hampl C Sternberg S Berweck, et al. 2002 Regression of left ventricular hypertrophy in hemodialysis patients is possible Clin Nephrol 58 Suppl 1 S73 S96 12227731
90. C Gouva P Nikolopoulos JPA Ioannidis KC Siamopoulos 2004 Treating anemia early in renal failure patients slows the decline of renal functional: a randomized controlled trial Kidney Int 66 753 760 10.1111/j.1523-1755.2004. 00797.x 15253730 (Pubitemid 38982019)
91. TC Mix RM Brenner ME Cooper D de Zeeuw P Ivanovich AS Levey JB McGill JJ McMurray PS Parfrey HH Parving BJ Pereira G Remuzzi AK Singh SD Solomon C Stehman-Breen RD Toto MA Pfeffer 2005 Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease Am Heart J 149 408 413 10.1016/j.ahj.2004.09.047 1:CAS:528:DC%2BD2MXis1Gkt7s%3D 15864229 (Pubitemid 40585402)
92. AK Singh L Szczech KL Tang H Barnhart S Sapp M Wolfson D Reddan CHOIR Investigators 2006 Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 2085 2098 10.1056/NEJMoa065485 1:CAS:528: DC%2BD28Xht1Wqt7fN 17108343 (Pubitemid 44749317)
93. SD Anker R Toto 2009 Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients NDT Plus 2 i3 i8 10.1093/ndtplus/sfn174 1:CAS:528:DC%2BD1MXit1Cht74%3D 19461857
94. Young JB, Anand IS, Diaz R et al. Reduction of events with darbepoetin alfa in heart failure (RED-HF)TM Trial [abstract 950169]. Presented at 10th Annual Scientific Meeting of the Heart Failure Society of America, Seattle, Washington, 10-13 September 2006.
95. G Marenzi G Lauri M Grazi E Assanelli J Campodonico P Agostoni 2001 Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure J Am Coll Cardiol 38 963 968 10.1016/S0735-1097(01)01479-6 1:STN:280:DC%2BD3Mrjs1Wluw%3D%3D 11583865 (Pubitemid 32912695)
96. M Guglin L Polavaram 2007 Ultrafiltration in heart failure Cardiol Rev 5 226 230 10.1097/CRD.0b013e31812e4b26 (Pubitemid 47282031)
97. MR Costanzo ME Guglin MT Saltzberg ML Jessup BA Bart JR Teerlink BE Jaski JC Fang ED Feller GJ Haas AS Anderson MP Schollmeyer PA Sobotka UNLOAD Trial Investigators 2007 Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure J Am Coll Cardiol 6 675 683 10.1016/j.jacc.2006.07.073 (Pubitemid 46205043)
98. JH Ellis RH Cohan 2009 Reducing the risk of contrast-induced nephropathy: a prospective on the controversies Am J Roentgenol 192 1544 1549 10.2214/AJR.09.2368
99. G Dangas I Iakovou E Nikolsky ED Aymong GS Mintz NN Kipshidze AJ Lansky I Moussa GW Stone JW Moses MB Leon R Mehran 2005 Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables Am J Cardiol 95 13 19 10.1016/j.amjcard.2004.08.056 15619387 (Pubitemid 40051105)
100. C Kistorp I Raymond F Pedersen F Gustafsson J Faber P Hildebrandt 2005 N-terminal pro-brain natriuretic pepetide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults JAMA 293 1609 1616 10.1001/jama.293.13.1609 1:CAS:528: DC%2BD2MXjtV2qsrg%3D 15811980 (Pubitemid 40471791)